SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-000838
Filing Date
2020-02-14
Accepted
2020-02-14 16:31:25
Documents
74
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20191231x10q.htm 10-Q 1555536
2 EX-31.1 otlk-20191231ex3111f15a3.htm EX-31.1 13677
3 EX-32.1 otlk-20191231ex321a97cf9.htm EX-32.1 9110
  Complete submission text file 0001558370-20-000838.txt   6971038

Data Files

Seq Description Document Type Size
4 EX-101.INS otlk-20191231.xml EX-101.INS 1505511
5 EX-101.SCH otlk-20191231.xsd EX-101.SCH 54846
6 EX-101.CAL otlk-20191231_cal.xml EX-101.CAL 60736
7 EX-101.DEF otlk-20191231_def.xml EX-101.DEF 214302
8 EX-101.LAB otlk-20191231_lab.xml EX-101.LAB 455048
9 EX-101.PRE otlk-20191231_pre.xml EX-101.PRE 407464
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 20620776
SIC: 2836 Biological Products, (No Diagnostic Substances)